ArticleFrontiers in medicine2026
Evolution of therapy for autoimmune diseases in pregnancy: a retrospective study from 2000 to 2023.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Treatment options for rheumatic diseases in pregnancy have consistently changed over the years. The most common therapies for autoimmune diseases during pregnancy include low-dose aspirin (LDA), low-molecular-weight heparin (LMWH), steroids, and hydroxychloroquine (HCQ). Therapy choice is based on obstetrical history, presence of antiphospholipid antibodies, and disease severity and refractoriness. Over the years, we have observed a decrease in glucocorticoid administration and an increase in HCQ administration. Glucocorticoid therapy during pregnancy can increase the risk of premature rupture of membranes and intrauterine growth restriction. In mothers, it is correlated with gestational hypertension, diabetes, osteoporosis, and infections. HCQ appears safe in pregnancy for fetal development and growth; it may improve pregnancy outcomes and reduce the risk of preeclampsia and autoimmune disease flares. Methods: We conducted a retrospective study of 266 pregnant women affected by autoimmune diseases (systemic lupus erythematosus, antiphospholipid syndrome, Sjogren's Syndrome, connective tissue disease) referred to our center from 2000 to 2023. Results: We observed substantial stability in LDA use, ranging from 100% in 2000-2003 to 96% in 2020-2023 (mean 88%; p 0.54). Regarding LMWH, we observed a modest but consistent increase, starting from 25% in 2000-2003 to 61% in 2020-2023 (mean 50%; Conclusion: These changes in therapy reflect increased knowledge in autoimmune diseases during pregnancy, with a more consistent number of women able to have and carry a pregnancy despite their disease severity. Over the years, our center had offered the best therapeutic management to achieve a good obstetrical outcome and minimize the incidence of obstetrical complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.